Skip to main content

Outage notice:

Due to the global information outage that occurred Friday, Quest is taking swift action to respond, recover and restore our operations. Our Patient Services are operating with reduced capacity so you may experience longer wait and service times. Our Customer Contact teams are currently unavailable. We appreciate your patience as we work toward returning to normal operations. 

Hide

Community Health Centers

Our commitment to community health centers

Health centers are among the many unsung heroes of our health care system. Your commitment to the well-being of those who experience significant barriers to care deserves—and requires—an approach that makes quality care more attainable while controlling costs for you and your patients.

Let us help you make the most of your opportunities

Working with Quest Diagnostics, community clinics and health centers can optimize operational efficiency, achieve continuous quality improvement, break down affordability barriers for medically underserved populations, provide comprehensive care that includes education, prevention, disease management, and maximize funding streams. This is how we’ll do it together:

Our FQHC services can help create sustainable improvements in quality care for the needs of your unique population

Help to meet quality measures whether your patients’ needs are routine or complex with age-based smart codes that automatically select the right tests, and cervical cancer co-tests, that check for high-risk HPV.

Manage disease in high-risk populations with clinical algorithms that help make earlier diagnoses for conditions such as asthma, HIV, and viral hepatitis, using specialized IDI testing that is often faster and more accurate.

Help close care gaps with simple at-home CRC screening, genetic testing for hereditary cancers, and professional consultations with geneticists and genetic counselors.

Identify people at risk for cardiometabolic diseases such as prediabetes and type 2 diabetes earlier to help prevent costly—and devastating—outcomes with tests and panels that identify early insulin resistance and metabolic risk.

Better serve the complex needs of your most at-risk patients with clinical drug monitoring (CDM) that helps you manage prescribed controlled substances, identify potential misuse of legal or illicit drugs, and screen for infectious disease.

Let us help with your COVID-19 recovery program

Communities will continue to count on health centers like yours to fight COVID-19. Quest can help.

Contact us

Count on Quest for a smooth transition

As the world’s leading provider of diagnostic information services, we’ve worked with many community health centers with limited resources to navigate change. We’ve created a process that streamlines your transition to Quest, assuring you of consistent service levels with minimal disruption to patients and providers. And we’ll work closely with you to customize the implementation to your specific needs and realities.

Let’s talk about your needs

We can help you balance quality care for your community while protecting your viability.

Contact us

A resilient recovery and collaborative future

Community health centers and Quest are working together to provide the solutions needed to fight COVID-19.

Download our COVID-19 recovery brochure

Community health centers by the numbers

<45%

of community health center patients are screened for colorectal cancer (CRC)1

50%+

of persons who inject drugs reportedly infected with HCV2

59%+

higher detection of high-grade lesions with ThinPrep Pap test vs conventional pap testing3

24%+

reduction in false positives in Aptima HPV mRNA testing vs HPV DNA testing4-5

1 National Colorectal Cancer Roundtable. CRC screening rates reach 44.4% in FQHCs in 2018. https://nccrt.org/colorectal-cancer-screening-rates-reach-44-1-in-fqhcs-in-2018/ Accessed July 13, 2020. 

2 Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192-1207.

3 ThinPrep 2000 system [package insert]. MAN-02624-001 Rev.004. Marlborough, MA; Hologic, Inc.; 2017.

4-5 Monsonego J, Hudgens MG, Zerat L, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer. 2011;29(3):691-701. doi: 10.1002/ijc.25726  5. Cuzick J, Cadman L, Mesher D, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108(4):908-913. doi: 10.1038/bjc.2013.22